Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214811 · ClinicalTrials.gov registry record · Phase 3
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
A Phase 3 study of Inflammation and Burns, sponsored by Molnlycke Health Care AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT01214811: Completed Phase 3 study of Inflammation and Burns, sponsored by Molnlycke Health Care AB.
NCT01214811 is a Phase 3 study of Inflammation and Burns that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 27 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01214811, a Phase 3 study of Inflammation and Burns, has completed, sponsored by Molnlycke Health Care AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need\* of topical antimicrobial treatment according to the physician.
Conditions Studied
Interventions
- DEVICE Mepilex Border Ag
Study Locations (3)
Alabama
- Institute for advanced wound care - Momtgomery
Iowa
- Burn treatment center - Iowa City
New York
- Center for Curative & Palliative Care, Calvary Hospital - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
What the finished NCT01214811 record still lists
NCT01214811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Mepilex Border Ag is the first listed.
NCT01214811 reports a single indexed study location in Alabama, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT01214811 about?
NCT01214811 is a clinical study titled "Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing". The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need\* of topical antimicrobial treatment...
What is the current status of trial NCT01214811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2010-09. Estimated completion is 2011-12.
What conditions does trial NCT01214811 study?
This clinical trial studies the following conditions: Inflammation, Burns, Ulcers.
What interventions are being tested in trial NCT01214811?
The interventions under investigation include: Mepilex Border Ag (DEVICE).
Who is sponsoring clinical trial NCT01214811?
This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01214811 being conducted?
This trial has 3 study locations across Alabama, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01214811's enrollment target sits among peer trials
27 112th of 132 higher than 21 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
COMPLETED · Phase 3
-
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia